|
|
Zhaosheng Lin
Head of Biomarkers
Pfizer
 Nadine Cohen Head of Pharmacogenomics
Johnson & Johnson
 Mitchell B. Friedman Director of Toxicology
Takeda Global R&D
 Malcolm Mitchell Medical Director, Clinical Pharmacology
Eli Lilly
 Dr Russell Weiner Group Director
Bristol-Myers Squibb
|
Conference:
Pre-conference workshop
19 Oct 9am - 5pm
Day 1
20 Oct 8.30am - 5:30pm
Day 2
21 Oct 8.30am - 5:30pm
Post-conference workshop
22 Oct 9am - 5pm
Venue: Boston, MA, United States
› Email a friend
› Add this to my calendar
|
|
|
 Dr. Terri Binder,
Director Imaging Oncology Eisai Terri Binder, MS, DMD, PhD has been Director, Imaging Biomarkers, Oncology at Eisai since February 2009. Prior to joining Eisai, she was at Amgen Inc. for 11 years, where she spent two years focusing on imaging science and imaging biomarker development in Phase 0, 1 and 2a studies. She created her previous position of Medical Imaging Manager in 2002 where she was a primary technical liaison between Clinical Study Teams and Medical Imaging Core Laboratories, focusing on Phase 2 and 3 studies. Before focusing solely on medical imaging in clinical trials, Dr. Binder was a Clinical Study Manager for trials that utilized medical imaging endpoints, and wrote an Amgen internal Guide to Managing Clinical Trials with Imaging Components. Before joining Amgen, Dr. Binder was a Clinical Manager at Block Drug Company, where she was responsible for clinical trials using digital subtraction radiography to assess oral bone loss.
Terri received her BS from Cornell University, MS from Harvard School of Public Health, DMD from Harvard School of Dental Medicine, PhD in Immunology from University of Connecticut, and a Certificate of Periodontics from Columbia University School of Dental and Oral Surgery. Before her pharmaceutical industry career, she was an Assistant Professor at Columbia University School of Dental and Oral Surgery for four years, combining teaching and research, and practicing Periodontics in a private dental office one day a week.
Terri is a member of DIA as well as several professional dental organizations
Appearing: Day Two, Thursday 21 October 2010 3.45pm How Imaging in Can Aid Decision Making in Early Clinical Development
- Does the drug reach/cover the intended target
- Does the drug affect the hypothesized biological pathway
- Does the biological effect lead to the desired clinical effect
Dr. Terri Binder, Director Imaging Oncology,
Eisai |
|
|
|
|
|
Reserve an exhibition stand at the Exploratory Clinical Development World Americas exhibition - book early to ensure optimum stand placement!
| |
Reserve a stand
For details contact
Claire Conway on +44 (0) 207 608 7058 |
|
|
|
|
|
|
|
|
|
